Objective: To determine the population-based utilization rate of electroconvulsive therapy (ECT) in Victoria between 1998-1999, to examine the characteristics of the ECT treated group, and to identify patient factors independently associated with differential rates of ECT treatment.
Method: Electroconvulsive therapy is reported under statute in Victoria, Australia. Crude, age-adjusted and age-sex specific utilization rates were calculated using this statutory data for the 1998-1999 financial year and estimated mid-year populations from the Australian Bureau of Statistics. Descriptive characteristics of those treated with ECT were derived from the statutory data. Patient factors associated with an increased likelihood of ECT in the public sector were explored with logistic regression analysis, using non-ECT treated mental health patients from the Victorian Psychiatric Case Register as the reference population.
Results: The crude treated-person and age-adjusted rates for the State (both public and private sectors) were 39.9 and 44.0 persons per 100 000 resident population per annum, respectively. The crude and age-adjusted administration rates were 330.3 and 362.6 ECT administrations per 100 000 resident population per annum, respectively. Age-sex specific rates varied by age and sex, with rates generally increasing with age and female sex. Overall, 62.8% of the treated group were women, 32.9% aged over 64, and 75.2% had depression. Diagnosis, age and sex each independently predicted ECT in the public sector, with diagnosis the most important factor, followed by age then sex.
Conclusions: Despite decades of use, the appropriate rate of ECT utilization is still unclear. Further research should be directed at exploring the factors, including provider variables, determining ECT treatment.
Download full-text PDF |
Source |
---|---|
http://dx.doi.org/10.1046/j.1440-1614.2003.01182.x | DOI Listing |
J Affect Disord
January 2025
Department of Anesthesiology and Intensive Care Medicine, Medical University of Innsbruck, Austria. Electronic address:
Background: Anesthesia depth influences seizure quality in patients undergoing electroconvulsive therapy (ECT). EEG-based neuromonitoring has been shown to detect adequate anesthesia depth for ECT. Anesthesia depth-guided ECT management may therefore be a reliable alternative to the predetermined anesthesia-to-stimulation time interval.
View Article and Find Full Text PDFJ ECT
January 2025
From the Department of Psychiatry and Behavioral Sciences, Emory University School of Medicine, Atlanta, GA.
Background: Electroconvulsive therapy (ECT) is an effective treatment for treatment-resistant depression (TRD). There are limited data on the improvement of anxiety symptoms in patients receiving ECT for TRD.
Objective: The aim of the study was to examine the extent to which anxiety symptom severity improves, relative to improvements in depressive symptoms, in TRD patients receiving an acute course of ECT.
There remains a scarcity of studies to evaluate the treatment effect of electroconvulsive therapy (ECT). Functional near-infrared spectroscopy (fNIRS) offers a cost-effective method to measure cerebral hemodynamics. This study used fNIRS to evaluate the effect of ECT in patients suffering from schizophrenia or bipolar disorder (manic phase).
View Article and Find Full Text PDFJ ECT
January 2025
From the Mayo Clinic, Department of Psychiatry and Psychology, Rochester, MN.
Electroconvulsive therapy (ECT) is an effective treatment for severe depression, especially in treatment-resistant cases. However, its potential cognitive side effects necessitate careful dosing to balance therapeutic benefits and cognitive stability. Recent advances in electric field (E-field) modeling offer promising avenues to optimize ECT dosing.
View Article and Find Full Text PDFJ ECT
January 2025
From the Department of Psychiatry, University Medical Centre Groningen, University of Groningen, Groningen, the Netherlands.
Objectives: This study investigates repeated oral esketamine as a substitution strategy for maintenance electroconvulsive therapy (M-ECT) in eight patients with treatment-resistant depression (TRD).
Methods: In a 6-week dosing phase, esketamine was titrated from 0.5 or 1.
Enter search terms and have AI summaries delivered each week - change queries or unsubscribe any time!